These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 1912374)
21. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940 [TBL] [Abstract][Full Text] [Related]
22. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. Economopoulos T; Mellou S; Papageorgiou E; Pappa V; Kokkinou V; Stathopoulou E; Pappa M; Raptis S Leukemia; 1999 Jul; 13(7):1009-12. PubMed ID: 10400415 [TBL] [Abstract][Full Text] [Related]
23. Myelodysplasia and the leukemias. Jacobs P Dis Mon; 1997 Aug; 43(8):505-97. PubMed ID: 9301644 [TBL] [Abstract][Full Text] [Related]
24. Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes. Nand S; Ellis T; Messmore H; Fisher SG; Gaynor E; Fisher RI Leukemia; 1992 Mar; 6(3):220-3. PubMed ID: 1564960 [TBL] [Abstract][Full Text] [Related]
25. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Runde V; de Witte T; Arnold R; Gratwohl A; Hermans J; van Biezen A; Niederwieser D; Labopin M; Walter-Noel MP; Bacigalupo A; Jacobsen N; Ljungman P; Carreras E; Kolb HJ; Aul C; Apperley J Bone Marrow Transplant; 1998 Feb; 21(3):255-61. PubMed ID: 9489648 [TBL] [Abstract][Full Text] [Related]
26. Ubenimex in the treatment of acute nonlymphocytic leukemia in adults. Urabe A; Mutoh Y; Mizoguchi H; Takaku F; Ogawa N Ann Hematol; 1993 Aug; 67(2):63-6. PubMed ID: 8347731 [TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic syndromes: the pediatric point of view. Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722 [TBL] [Abstract][Full Text] [Related]
29. Cyclosporin A in myelodysplastic syndrome: a preliminary report. Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884 [TBL] [Abstract][Full Text] [Related]
30. CD34/QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes. Baur AS; Meugé-Moraw C; Schmidt PM; Parlier V; Jotterand M; Delacrétaz F Eur J Haematol; 2000 Feb; 64(2):71-9. PubMed ID: 10997326 [TBL] [Abstract][Full Text] [Related]
31. Translocation (3;21) characterizes crises in myeloid stem cell disorders. Chen Z; Morgan R; Baer MR; Ligorsky R; Sandberg AA Cancer Genet Cytogenet; 1991 Dec; 57(2):153-9. PubMed ID: 1756492 [TBL] [Abstract][Full Text] [Related]
32. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227 [TBL] [Abstract][Full Text] [Related]
33. Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal. Nüssler V; Pelka-Fleischer R; Zwierzina H; Nerl C; Beckert B; Gullis E; Gieseler F; Bock S; Bartl R; Petrides PE Ann Hematol; 1994; 69 Suppl 1():S25-9. PubMed ID: 7914749 [TBL] [Abstract][Full Text] [Related]
34. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Tamaki H; Ogawa H; Ohyashiki K; Ohyashiki JH; Iwama H; Inoue K; Soma T; Oka Y; Tatekawa T; Oji Y; Tsuboi A; Kim EH; Kawakami M; Fuchigami K; Tomonaga M; Toyama K; Aozasa K; Kishimoto T; Sugiyama H Leukemia; 1999 Mar; 13(3):393-9. PubMed ID: 10086730 [TBL] [Abstract][Full Text] [Related]
35. Thalidomide for the treatment of patients with myelodysplastic syndromes. Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256 [TBL] [Abstract][Full Text] [Related]
36. Primary myelodysplastic syndrome: an analysis of 56 patients. Chen PH; Kuo CY; Huang CH; Shih LY Changgeng Yi Xue Za Zhi; 1992 Sep; 15(3):121-7. PubMed ID: 1468034 [TBL] [Abstract][Full Text] [Related]
37. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032 [TBL] [Abstract][Full Text] [Related]
38. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia. Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021 [TBL] [Abstract][Full Text] [Related]
39. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes. Gyger M; Infante-Rivard C; D'Angelo G; Forest L; Lussier P Am J Hematol; 1988 May; 28(1):13-20. PubMed ID: 3369432 [TBL] [Abstract][Full Text] [Related]
40. High prevalence of human T-lymphotropic virus type I carriers among patients with myelodysplastic syndrome refractory anemia with excess of blasts (RAEB), RAEB in transformation and acute promyelocytic leukemia. Inoue H; Matsushita K; Arima N; Hamada H; Uozumi K; Ozaki A; Akimoto M; Kawada H; Kukita T; Yoshimitsu M; Matsumoto T; Tei C Leuk Lymphoma; 2008 Feb; 49(2):315-21. PubMed ID: 18231919 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]